BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Bayer expects 2025 to be the most difficult year of its turnaround
Awards highlight Avantor's commitment to the Biopharma industry
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
There are 38.4 million people with diabetes in the United States
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
